PRLDHealthcareMicro-Cap

Prelude Therapeutics Inc Insider Trading Activity

Every SEC Form 4 insider transaction reported for Prelude Therapeutics Inc (PRLD), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are PRLD insiders buying or selling?

Prelude Therapeutics Inc insiders reported 29 open-market buys ($113.6M) and 28 sells ($10.4M) across 57 Form 4 filings — a net buying position of $103.2M.

Source: SEC EDGAR Form 4

Key Statistics (as of Apr 23, 2026)

Total Form 4 filings
57
SEC EDGAR
Insider filers
14
Insider buys (29)
$113.6M
Insider sells (28)
$10.4M

Insider sentiment

Net buying

Net insider flow of $103.2M in net buying. 2 insider buys in the last 90 days.

Recent PRLD insider transactions

DateInsiderRoleTypeSharesPriceValue
Apr 23, 2026David P BonitaDirector, 10% OwnerPurchase2.8M$4.44$12.5M
Apr 23, 2026ORBIMED ADVISORS LLCDirector, 10% OwnerPurchase2.8M$4.44$12.5M
Mar 27, 2025Andrew CombsChief Chemistry OfficerPurchase100.0K$0.69$69.3K
Mar 27, 2025Vaddi KrishnaCEOPurchase675.0K$0.69$467.4K
Mar 24, 2025Vaddi KrishnaCEOPurchase20.4K$0.73$14.9K
Mar 18, 2025Vaddi KrishnaCEOPurchase39.1K$0.75$29.5K
Mar 14, 2025Vaddi KrishnaCEOPurchase97.5K$0.71$69.6K
Jan 3, 2025Vaddi KrishnaCEOPurchase5.0K$1.21$6.0K
Jan 2, 2025Vaddi KrishnaCEOPurchase10.0K$1.20$12.0K
Dec 26, 2024Andrew CombsChief Chemistry OfficerPurchase63.1K$1.36$85.5K
Dec 20, 2024Bryant David LimCLO, Interim CFO, Corp Sec.Purchase25.0K$0.91$22.6K
Dec 20, 2024Vaddi KrishnaCEOPurchase106.9K$0.93$99.3K
May 26, 2023Vaddi KrishnaCEOPurchase1.9K$5.15$9.8K
May 25, 2023Bryant David LimChief Legal Officer, Corp Sec.Purchase2.4K$5.39$12.9K
May 25, 2023Laurent ChardonnetChief Financial OfficerPurchase5.0K$5.50$27.5K
May 25, 2023Vaddi KrishnaCEOPurchase11.9K$5.63$66.7K
May 24, 2023ORBIMED ADVISORS LLCDirector, 10% OwnerPurchase869.6K$5.75$5.0M
May 24, 2023David P BonitaDirector, 10% OwnerPurchase869.6K$5.75$5.0M
Apr 6, 2023Jane HuangPresident, CMOSale13.3K$6.12$81.3K
Dec 21, 2022Vaddi KrishnaCEOPurchase19.2K$5.13$98.4K
Dec 12, 2022Laurent ChardonnetChief Financial OfficerPurchase10.0K$4.76$47.6K
Jun 1, 2022Laurent ChardonnetChief Financial OfficerPurchase10.0K$4.23$42.3K
Dec 17, 2021Deborah MorosiniEVP, Chief of Clinical AffairsSale28.8K$13.00$373.8K
Dec 15, 2021Andrew CombsEVP, Head of ChemistryPurchase8.0K$11.86$94.9K
Nov 18, 2021Deborah MorosiniEVP, Chief of Clinical AffairsSale28.8K$15.88$456.5K

Showing the 25 most recent of 57 Form 4 filings for Prelude Therapeutics Inc.

Most active PRLD insiders

  • David J Mauro10 filings
  • Vaddi Krishna10 filings
  • Deborah Morosini6 filings
  • Peggy Scherle6 filings
  • Christopher Pierce5 filings

Ask anything about PRLD insider activity

Use Trabud's AI agent to query Prelude Therapeutics Inc's Form 4 history in plain English — "Show me PRLD CEO purchases this year" or compare it against any other ticker.

Open the AI agent

PRLD insider trading FAQ

Are Prelude Therapeutics Inc insiders buying or selling?

Across 57 SEC Form 4 filings, Prelude Therapeutics Inc (PRLD) insiders reported 29 open-market purchases totaling $113.6M and 28 sales totaling $10.4M. That is a net buying position of $103.2M.

How many insiders trade PRLD stock?

14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Prelude Therapeutics Inc. The most recent filing was accepted on Apr 23, 2026.

Where does Trabud get PRLD insider trading data?

All PRLD insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content